BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zucca LE, Morini Matushita MA, da Silva Oliveira RJ, Scapulatempo-Neto C, de Lima MA, Ribeiro GG, Viana CR, Cárcano FM, Reis RM. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol 2018;36:11.e13-21. [PMID: 28986088 DOI: 10.1016/j.urolonc.2017.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Stone L. Kidney cancer: AXL expression predicts prognosis. Nat Rev Urol 2017;14:700. [PMID: 29116257 DOI: 10.1038/nrurol.2017.186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Signoretti S, Flaifel A, Chen YB, Reuter VE. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol 2018;:JCO2018792259. [PMID: 30372384 DOI: 10.1200/JCO.2018.79.2259] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
3 Chen XY, Lan M, Zhou Y, Chen WZ, Hu D, Liu JM, Huang SH, Liu ZL, Zhang ZH. Risk factors for bone metastasis from renal cell cancer. J Bone Oncol 2017;9:29-33. [PMID: 29159028 DOI: 10.1016/j.jbo.2017.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
4 Tanaka M, Dykes SS, Siemann DW. Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling. Clin Exp Metastasis 2021;38:321-35. [PMID: 33791875 DOI: 10.1007/s10585-021-10093-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Borchiellini D. Cancer du rein métastatique : quels critères de choix en 2e ligne ? Bull Cancer 2018;105 Suppl 3:S242-54. [PMID: 30595153 DOI: 10.1016/S0007-4551(18)30379-5] [Reference Citation Analysis]
6 Xu D, Sun D, Wang W, Peng X, Zhan Z, Ji Y, Shen Y, Geng M, Ai J, Duan W. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. Eur J Med Chem 2021;220:113497. [PMID: 33957388 DOI: 10.1016/j.ejmech.2021.113497] [Reference Citation Analysis]
7 Hashmi F, Mollapour M, Bratslavsky G, Bourboulia D. MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer. Urol Oncol 2021;39:316-21. [PMID: 32487351 DOI: 10.1016/j.urolonc.2020.04.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Chen TJ, Mydel P, Benedyk-Machaczka M, Kamińska M, Kalucka U, Blø M, Furriol J, Gausdal G, Lorens J, Osman T, Marti HP. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiol Rep 2021;9:e15140. [PMID: 34877810 DOI: 10.14814/phy2.15140] [Reference Citation Analysis]
9 Park M, Kang KW. Phosphatidylserine receptor-targeting therapies for the treatment of cancer. Arch Pharm Res 2019;42:617-28. [PMID: 31172440 DOI: 10.1007/s12272-019-01167-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
10 Chakraborty S, Balan M, Sabarwal A, Choueiri TK, Pal S. Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochim Biophys Acta Rev Cancer 2021;1876:188559. [PMID: 33965513 DOI: 10.1016/j.bbcan.2021.188559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gomes AM, Carron EC, Mills KL, Dow AM, Gray Z, Fecca CR, Lakey MA, Carmeliet P, Kittrell F, Medina D, Machado HL. Stromal Gas6 promotes the progression of premalignant mammary cells. Oncogene 2019;38:2437-50. [PMID: 30531835 DOI: 10.1038/s41388-018-0593-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
12 Mubarak MF, Daglilar ES, Smilari T, Ray A. Metastatic Renal Cell Carcinoma Presenting as a Bleeding Gastric Polyp. Ochsner J 2018;18:274-6. [PMID: 30275795 DOI: 10.31486/toj.17.0086] [Reference Citation Analysis]
13 Xu Y, Zhang Y, Wang X, Kang J, Liu X. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Cancer 2019;19:168. [PMID: 30795756 DOI: 10.1186/s12885-019-5375-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
14 Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin Ther Targets 2021;25:141-51. [PMID: 33356674 DOI: 10.1080/14728222.2021.1869212] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]